Acurx Announces Positive Comparative Microbiology and Microb

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin...

Related Keywords

United States , University Of Houston , Texas , Houston , America , Davidp Luci , Kevin Garey , Robertj Deluccia , Acurx Pharmaceuticals , Society Or Healthcare Epidemiology Of America , Company Ph , Company Scientific Advisory Board , Exchange Commission , Data Monitoring Committee , University Of Houston College Pharmacy , Trial Oversight Committee , European Medicines Agency , Drug Administration , Nasdaq , Exchange Commission On Form , Acurx Pharmaceuticals Inc , Infectious Diseases Society Of America , Extended Clinical Cure , Gulf Coast Consortia Antimicrobial Resistance , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Double Blind Study , Ibezapolstat Compared , Executive Chairman , Ibezapolstat Phase , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Private Securities Litigation Reform Act , Nc ,